表紙
市場調査レポート

コンパニオン診断薬市場

Companion Diagnostics Market (2nd Edition), 2014 - 2024

発行 ROOTS ANALYSIS 商品コード 282859
出版日 ページ情報 英文 233 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
コンパニオン診断薬市場 Companion Diagnostics Market (2nd Edition), 2014 - 2024
出版日: 2014年06月05日 ページ情報: 英文 233 Pages
概要

世界のコンパニオン診断薬市場は今後10年間で年率22.9%の成長が見込まれており、さまざまな適応症において、2024年まで年間1,000万回以上の試験が実施されると予測されています。2013年における上市コンパニオン診断薬の収益は、260億米ドル以上と推計されています。

当レポートでは、コンパニオン診断薬市場の動向について調査し、個別化医療診断とコンパニオン診断との違い、従来の医療を凌ぐ個別化医療の利点、上市・パイプラインコンパニオン診断検査の評価、併用薬市場の現況などの分析を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 内容・背景
  • 従来の医療・診断: One for All のコンセプト
  • バイオテクノロジーのマイルストーン:ヒト遺伝子情報の解読
  • 医療の側面の変化:個別化医療・診断

第4章 コンパニオン診断薬市場

  • 本章の概要
  • 新規化合物の15.8%FDAから薬理ゲノムバイオマーカーとして認可
  • 市場におけるコンパニオン診断薬
  • ケーススタディ

第5章 世界のコンパニオン診断薬市場

  • 本章の概要
  • コンパニオン診断薬:定義
  • 上市済みのコンパニオン診断薬
  • パイプラインにおけるコンパニオン診断薬
  • 予測手法
  • 世界のコンパニオン診断薬市場:試験タイプ別
  • 世界のコンパニオン診断薬市場:適応症タイプ別

第6章 コンパニオン診断薬の地域別市場

  • 本章の概要
  • 米国
  • 欧州
  • EU5ヶ国
  • 日本
  • その他

第7章 主要企業のプロファイル

  • 本章の概要
  • Qiagen
  • Dako (Agilent Technologiesの子会社)
  • Roche Laboratories
  • Novartis
  • bioMerieux

第8章 セラノスティクス市場:ステークホルダー・ビジネスモデル

  • 本章の概要
  • 市場におけるステークホルダー
  • セラノスティクス開発企業

第9章 市場成長促進因子

  • 本章の概要
  • 低い薬剤有効率
  • 薬剤コンプライアンスの低さ
  • 創薬の高コスト
  • フェーズII・III薬剤の失敗
  • 薬剤リコール
  • コンパニオン診断薬への移行を可能にするツール・技術
  • SWOT分析

第10章 インタビュー記録

第11章 結論

第12章 付録1:表

第13章 付録2:企業・組織リスト

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10015

With an influx of new technologies and increasing awareness about personalized medicine, the pharmaceutical industry has steadily started to adopt a more customized drug development model. The concept of companion diagnostics holds huge potential for pharma companies as well as medical community. This new approach to medication is expected to transform healthcare by improving treatment outcomes, eliminating adverse reactions and reducing cost and time barriers associated with the conventional methods of medication.

In fact, targeted drugs have been fast to overshadow traditional drugs, which favour the concept of one-size-fits-all. Several targeted drugs are being developed in association with a companion diagnostic test and have reached blockbuster status despite targeting a limited audience. Both large and small biopharmaceutical companies are now actively developing drug-diagnostic combination products. The success of Herceptin and Glivec has proved that the benefits of use of companion diagnostics far outweigh the challenge of a limited target population. There are ample opportunities for growth in this niche market for both pharmaceutical and diagnostic companies.

The journey of a biomarker to a companion diagnostic is a long one, with the regulatory authorities favouring the co-development and approval of companion drug and diagnostic. Although complex, the pipeline for companion diagnostics is rich. In the future, the launch and success of drugs will also be governed by the successful development of a commercial companion diagnostic test. The 2014-2024 period is likely to see launch of many new companion diagnostics, transforming the promise into reality.

Synopsis

The ‘Companion Diagnostics Market (2nd Edition), 2014 - 2024’ report provides an extensive study of the growing market of companion diagnostics. The report differentiates personalized medicine diagnostics and companion diagnostics; we have separately defined these two closely associated markets. The research covers various aspects, such as, advantages of personalized medicine over traditional medicine and the need for companion diagnostics. In addition to evaluating the marketed and pipeline companion diagnostic tests, we have also provided our views on the current state of the companion drugs market.

One of the key objectives of this report is to understand the future evolution of the companion diagnostics market. Our proprietary ‘Companion Diagnostics Market Forecasting Model’ allows us to predict the likely growth of companion diagnostics tests across various parameters. The model, built over a ten year horizon, offers valuable insights on the following:

  • Global market evolution, both in terms of volume (number of tests) and the associated sales value (USD billion)
  • Regional variation, specifically in the US and European (Germany, Italy, France, Spain and the UK) markets
  • Likely adoption of marketed / pipeline tests for specific biomarkers (e.g. EGFR, KRAS, ALK, HER2 and BRAF) till 2024
  • Likely adoption of various marketed / pipeline tests for specific indications (e.g. metastatic non-small cell lung cancer, metastatic colorectal cancer, breast cancer and melanoma) till 2024

We have discussed, in detail, the key drivers behind the regional and global growth. The regional evaluation extends to other markets such as Japan, China and Australia. This provides a greater clarity in the differing approaches various regions have towards personalized medicine and companion diagnostics.

The research, analysis and insights presented in this report include the sales of all companion diagnostic tests that are essential before prescription of any companion drug. All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. The global companion diagnostics market is likely to grow at an annualized rate of 22.9% over the next ten years; by 2024, over 10 million tests are expected to be conducted annually across various indications.
  • 2. In 2013, 18.5% of the new molecular entities (NMEs) were approved with a pharmacogenomic biomarker by the FDA.
  • 3. The sales of marketed companion drugs generated estimated revenues of more than USD 26 billion in 2013, with six drugs achieving blockbuster status.
  • 4. The pipeline for companion diagnostics is rich with most products being developed with the collaborative effort of pharmaceutical and diagnostics companies; we have identified over 75 drugs which are being co-developed with predictive biomarkers.
  • 5. Partnership seems to be the most preferred model for development; since January 2011, there have been more than 90 collaborations between pharmaceutical and diagnostic companies.
  • 6. Pharmaceutical companies have displayed keen interest in companion diagnostic start-ups such as Epic Sciences and Nodality. Specifically, Epic Sciences has inked deals with at least six pharmaceutical companies (including Genentech, Celgene and Pfizer) for development of companion diagnostics for cancer drugs.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of companion diagnostics market.

Chapter 3 provides a general introduction on personalized medicine. We have also explained, in detail, companion diagnostics and their development from pharmacogenomics biomarkers.

Chapter 4 analyzes the global companion drugs market, including the FDA and EMA approved companion drugs. The chapter provides details on leading companion drugs and indications. It also highlights leading pharmaceutical companies active in this market, along with case studies of some well-known companion drugs.

Chapter 5 analyzes the global companion diagnostics market, identifying the currently marketed diagnostics and those in the pipeline. In this chapter, we have included our estimates on how the overall market is going to evolve globally over the next ten years. We adopted a bottom-up approach to forecast details on the number of tests and associated sales value for different biomarker and indication combinations.

Chapter 6 provides a detailed analysis on the regional market for companion diagnostics. The major markets covered include the US and Europe (Germany, France, Italy, Spain and the UK). We have also included details on companion diagnostic testing in Japan, China and Australia. The chapter highlights policies that govern the approval and reimbursement of in vitro diagnostics (in particular companion diagnostics) and investments made in the field of personalized medicine. In addition, we have identified the companion diagnostics approved in these countries, including the historical data on number of tests conducted in some of the regions. For the US and EU5 markets, we have provided our regional market forecast over the next ten years, both in terms of volume and value (by type of biomarker and by type of indication).

Chapter 7 includes profiles of the key companies in the companion diagnostics market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline products (including companion drugs and diagnostics) and recent developments.

Chapter 8 analyzes the theranostics market as a whole with detailed discussion on the role of various stakeholders in the market. We have also covered the recent partnerships that have taken place in the theranostics market to develop drug-diagnostic combinations.

Chapter 9 focuses on the key drivers of companion diagnostics, expanding on the advantages they hold for the delivery of healthcare. We have included a discussion on the tools and technologies promoting their use. The chapter also provides a SWOT analysis capturing the key elements likely to influence future growth.

Chapter 10 is a collection of transcripts of interviews conducted during the course of this study.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 12 and 13 are appendices. These provide tabulated data for all the figures provided in the report and a list of companies / organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Traditional Medicine and Diagnostics: The One for All Concept
  • 3.3. Milestone in Biotechnology: Decoding of Human Genetic Code in 2003
  • 3.4. Changing Face of Medicine: Personalized Medicine and Diagnostics
    • 3.4.1. Personalized Medicine vs. Traditional Medicine
    • 3.4.2. Personalized Medicine Diagnostics
    • 3.4.3. Pharmacogenomic Biomarkers
    • 3.4.4. Development of Biomarkers Into Companion Diagnostics
    • 3.4.5. The Three Entry Points for a Companion Diagnostic to Associate with a Drug
    • 3.4.6. Low Translation Rates of Biomarkers to Companion Diagnostics

4. COMPANION DRUGS MARKET, 2013

  • 4.1. Chapter Overview
  • 4.2. 18.5% of the New Molecular Entities were Approved with a Pharmacogenomic Biomarker by FDA
  • 4.3. Companion Drugs in the Market
    • 4.3.1. Companion Drugs in the Market have Achieved Blockbuster Status as Well
    • 4.3.2. Oncology was the Leading Indication Targeted by Companion Drugs
    • 4.3.3. Roche Laboratories had the Most Number of Successful Companion Diagnostics
  • 4.4. Case Studies
    • 4.4.1. Trastuzumab (Herceptin): A Successful Example of Personalized Medicine
    • 4.4.2. Crizotinib (Xalkori): From Conception to Market in Four Years
    • 4.4.3. Vemurafenib (Zelboraf): Co-development with Companion Diagnostic Accelerating the Time to Market
    • 4.4.4. Gefitinib (Iressa): Revival with Companion Diagnostic
    • 4.4.5. Kalydeco (Ivacaftor): Strong Start to a Promising Future

5. GLOBAL MARKET FOR COMPANION DIAGNOSTICS, 2014 - 2024

  • 5.1. Chapter Overview
  • 5.2. Companion Diagnostic: Definition
  • 5.3. Marketed Companion Diagnostics, 2014
    • 5.3.1. Preference of LDTs Over Kits
  • 5.4. Companion Diagnostics in Pipeline: Story of New Entrants
    • 5.4.1. Oncology Dominates the Pipeline as Well
    • 5.4.2. Collaboration of Drug-Diagnostic Developers is the Most Common Model
    • 5.4.3. Start-Ups Gaining Attention
    • 5.4.4. Companion Imaging Diagnostics on rise
  • 5.5. Forecast Methodology
  • 5.6. Global Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Test
    • 5.6.1. Global KRAS Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 5.6.2. Global EGFR Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 5.6.3. Global HER2 Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 5.6.4. Global ALK Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 5.6.5. Other Companion Diagnostics, 2014 - 2024: Number of Tests and Sales Forecast
  • 5.7. Global Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Indication
    • 5.7.1. Global Metastatic non-Small Cell Lung Cancer Companion Diagnostics Market, 2014 - 2024
    • 5.7.2. Global Metastatic Colorectal Cancer Companion Diagnostics Market, 2014 - 2024
    • 5.7.3. Global Breast Cancer Companion Diagnostics Market, 2014 - 2024
    • 5.7.4. Global Melanoma Companion Diagnostics Market, 2014 - 2024

6. REGIONAL MARKET FOR COMPANION DIAGNOSTICS, 2014 - 2024

  • 6.1. Chapter Overview
  • 6.2. United States
    • 6.2.1. Current FDA Classification of IVD Tests
    • 6.2.2. Companion Diagnostic Testing
    • 6.2.3. FDA Promoting the Development of Companion Diagnostics
    • 6.2.4. Overall US Market for Companion Diagnostics, 2014 - 2024
    • 6.2.5. The US KRAS Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.2.6. The US EGFR Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.2.7. The US HER2 Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.2.8. The US ALK Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.2.9. Other Companion Diagnostic Tests in the US, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.2.10. The US Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Indication
      • 6.2.10.1. The US Metastatic non-Small Cell Lung Cancer Companion Diagnostics Market, 2014 - 2024
      • 6.2.10.2. The US Metastatic Colorectal Cancer Companion Diagnostics Market, 2014 - 2024
      • 6.2.10.3 The US Breast Cancer Companion Diagnostics Market, 2014 - 2024
      • 6.2.10.4. The US Melanoma Companion Diagnostics Market, 2014 - 2024
  • 6.3. Europe (Germany, France, The UK, Italy, Spain)
    • 6.3.1. Regulation of IVDs in Europe: Current State
    • 6.3.2. Proposed Change in Classification to Alter the Regulation of Companion Diagnostics
    • 6.3.3. Other Proposed Changes
    • 6.3.4. Germany
      • 6.3.4.1. Companion Diagnostic Testing
      • 6.3.4.2. Investments in Personalized Healthcare
      • 6.3.4.3. Reimbursement System in Germany
    • 6.3.5. France
      • 6.3.5.1. Diagnostic Testing in France
      • 6.3.5.2. Reimbursement System in France
      • 6.3.5.3. Companion Diagnostic Testing
      • 6.3.5.4. Challenges in the French Companion Diagnostics Market
      • 6.3.5.5. Investments for Future Personalized Diagnostics
    • 6.3.6. The UK
      • 6.3.6.1. Diagnostic Testing in the UK
      • 6.3.6.2. State of HER2, KRAS and EGFR Testing
      • 6.3.6.3. Investments for Future Personalized Diagnostics
    • 6.3.7. Italy
    • 6.3.8. Spain
      • 6.3.8.1. Investments in the field of Personalized Healthcare
    • 6.3.9. Overall EU5 Market for Companion Diagnostics, 2014 - 2024
    • 6.3.10. EU5 KRAS Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.3.11. EU5 EGFR Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.3.12. EU5 HER2 Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.3.13. EU5 ALK Market, 2014 - 2024: Number of Tests and Sales Forecast
    • 6.3.14. Other Companion Diagnostics in EU5, 2014 - 2024: Number of Tests and Sales Forecast
  • 6.4. EU5 Companion Diagnostics Market, 2014 - 2024: Distribution by Type of Indication
    • 6.4.1. EU5 Metastatic non-Small Cell Lung Cancer Companion Diagnostics Market, 2014 - 2024
    • 6.4.2. EU5 Metastatic Colorectal Cancer Companion Diagnostics Market, 2014 - 2024
    • 6.4.3. EU5 Breast Cancer Companion Diagnostics Market, 2014 - 2024
    • 6.4.4. EU5 Melanoma Companion Diagnostics Market, 2014 - 2024
  • 6.5. Japan
    • 6.5.1. Companion Diagnostics Testing
    • 6.5.2. Growth Drivers
  • 6.6. Rest of the World
    • 6.6.1. Companion Diagnostic Testing in China: Tests and Companies
    • 6.6.2. Companion Diagnostic Testing in Australia
      • 6.6.2.1. Regulatory Framework in Australia
      • 6.6.2.2. Reimbursement Schemes
      • 6.6.2.3. Therapies and Companion Diagnostic Tests
      • 6.6.2.4. Investments in the field of Personalized Medicine

7. PROFILES OF LEADING COMPANIES

  • 7.1. Chapter Overview
  • 7.2. Abbott Molecular
    • 7.2.1. Marketed Companion Diagnostics
    • 7.2.2. Pipeline Companion Diagnostics
    • 7.2.3. Partnerships
    • 7.2.4. Financial Performance
  • 7.3. Qiagen
    • 7.3.1. Expanding Through Acquisitions
    • 7.3.2. Marketed Companion Diagnostics
    • 7.3.3. Pipeline Companion Diagnostics
    • 7.3.4. Partnerships
    • 7.3.5. Financial Performance
    • 7.3.6. Recent Developments
  • 7.4. Dako (a Subsidiary of Agilent Technologies)
    • 7.4.1. Marketed Products
    • 7.4.2. Pipeline Products
    • 7.4.3. Partnerships
    • 7.4.4. Financial Performance
    • 7.4.5. Recent Developments
  • 7.5. Roche Laboratories
    • 7.5.1. Marketed and Pipeline Products
      • 7.5.1.1. Marketed Products
    • 7.5.2. Pipeline Products
    • 7.5.3. Preferred Partner for Companion Diagnostics
    • 7.5.4. Financial Performance
  • 7.6. Novartis
    • 7.6.1. Marketed and Pipeline products
      • 7.6.1.1. Marketed products
      • 7.6.1.2. Pipeline Products
    • 7.6.2. Partnerships
    • 7.6.3. Financial Performance
  • 7.7. bioMérieux
    • 7.7.1. Expanding through Acquisitions
    • 7.7.2. Marketed and Pipeline Products
    • 7.7.3. Partnerships
    • 7.7.4. Financial Performance

8. ANALYSIS OF THERANOSTICS MARKET: STAKEHOLDERS AND BUSINESS MODELS

  • 8.1. Chapter Overview
  • 8.2. Stakeholders in the Market
  • 8.3. Theranostic Development Agencies
    • 8.3.1. Pharmaceutical Company
      • 8.3.1.1. Traits a Pharmaceutical Company Looks for in a Companion Diagnostics Developer
      • 8.3.1.2. Pharmaceutical Company Business Models
    • 8.3.2. The Companion Diagnostic Developer
      • 8.3.2.1. Companion Diagnostic Company Business Models
    • 8.3.3. Recent Partnerships
    • 8.3.4. Testing Laboratories
    • 8.3.5. Contract Research Organizations (CROs)
    • 8.3.6. Regulatory Authorities
    • 8.3.7. Buyers/Target Audience
    • 8.3.8. Payers
    • 8.3.9. Companies Providing Ancillary Services

9. MARKET GROWTH DRIVERS

  • 9.1. Chapter Overview
  • 9.2. Low Drug Efficacy Rates
  • 9.3. Poor Drug Compliance
  • 9.4. High Cost of Drug Development
  • 9.5. Phase II and III Drug Failures
  • 9.6. Drug Recalls
  • 9.7. Tools and Technologies Enabling the Move to Companion Diagnostics
    • 9.7.1. Growing Significance of Biomarkers
    • 9.7.2. Reducing Costs of Genome Sequencing
  • 9.8. SWOT Analysis
    • 9.8.1. Strengths
    • 9.8.2. Weaknesses
    • 9.8.3. Opportunities
    • 9.8.4. Threats

10. INTERVIEW TRANSCRIPTS

11. CONCLUSION

  • 11.1. Companion Diagnostics: An Emerging Market
  • 11.2. Co-Development and Approval of Companion Diagnostic will be the Preferred Route of Development
  • 11.3. Key Driving Factors
  • 11.4. Opportunities Outpace the Threats
  • 11.5. Concluding Remarks

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables:

  • Table 4.1: Companion Drugs Approved by FDA
  • Table 4.2: Companion Drugs Approved by the EMA
  • Table 5.1: List of Marketed Companion Diagnostic Tests, 2014
  • Table 5.2: List of Companion Diagnostics in Pipeline
  • Table 6.1: Proposed Classification of IVDs
  • Table 6.2: List of Companion Diagnostics Tests Conducted in France, 2013
  • Table 6.3: NICE Technology Appraisals of Drugs with Companion Diagnostics
  • Table 6.4: Japan's Population Over 65 - 2010, 2015 and 2020 (‘000, %)
  • Table 7.1: Abbott Molecular: Marketed Companion Diagnostic Tests
  • Table 7.2: Abbott Molecular: Pipeline Companion Diagnostic Tests
  • Table 7.3: Qiagen: Marketed Companion Diagnostic Tests
  • Table 7.4: Qiagen: Pipeline Companion Diagnostic Tests
  • Table 7.5: Dako: Marketed Companion Diagnostic Tests
  • Table 7.6: Roche: Marketed Companion Diagnostic Tests
  • Table 7.7: Novartis: Marketed Companion Drugs
  • Table 7.8: Novartis: Pipeline Companion Diagnostic Tests
  • Table 8.1: Deals and Collaborations for Companion Diagnostic Development, January 2011 - Present
  • Table 8.2: Companies providing Ancillary Services
  • Table 9.1: Drug Recalls from the US Market, 1996-2007
  • Table 9.2: SWOT Analysis of Companion Diagnostics Market
  • Table 12.1: List of New Molecular Entities (NMEs) Approved with Pharmacogenomic Biomarker
  • Table 12.2: Companion Drugs Market, 2013 - by Leading Drugs (USD million)
  • Table 12.3: Companion Drugs Market, 2013 - by Leading Indication (USD million, %)
  • Table 12.4: Companion Drugs Market, 2013- by Leading Companies (USD million, %)
  • Table 12.5: Herceptin Sales, 1998 - 2013 (USD million)
  • Table 12.6: Xalkori Sales, 2011- 2013 (USD Million)
  • Table 12.7: Zelboraf Sales, 2011- 2013 (USD Million)
  • Table 12.8: Iressa Sales, 2005 - 2013 (USD million)
  • Table 12.9: Kalydeco Sales, 2012- 2013 (USD Million)
  • Table 12.10: Global Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
  • Table 12.11: Global Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
  • Table 12.12: US Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
  • Table 12.13: US Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
  • Table 12.14: EU5 Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
  • Table 12.15: EU5 Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
  • Table 12.16: Global KRAS Market, Number of Tests, 2014 - 2024 (# '000)
  • Table 12.17: Global KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.18: Global EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.19: Global EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.20: Global HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.21: Global HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.22: Global ALK Market, Number of Tests, 2014 - 2024 (# '000)
  • Table 12.23: Global ALK Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.24: Other Companion Diagnostics, Global Number of Tests, 2014 - 2024 (# '000)
  • Table 12.25: Other Companion Diagnostics, Global Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.26: Global Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.27: Global Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.28: Global Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.29: Global Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.30: Global Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.31: Global Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.32: Global Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.33: Global Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.34: US Marketed and Pipeline Companion Diagnostics, Number of Tests: Split by Type of Test, 2014 - 2024 (# '000)
  • Table 12.35: US Marketed and Pipeline Companion Diagnostics, Sales Forecast: Split by Type of Test, 2014 - 2024 (USD MM)
  • Table 12.36: US KRAS Market, Number of Tests, 2014 - 2024 (# '000)
  • Table 12.37: US KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.38: US EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.39: US EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.40: US HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.41: US HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.42: US ALK Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.43: US ALK Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.44: Other Companion Diagnostics in the US, Number of Tests, 2014 - 2024 (# '000)
  • Table 12.45: Other Companion Diagnostics in the US, Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.46: US NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.47: US NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.48: US Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.49: US Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.50: US Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.51: US Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.52: US Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.53: US Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.54: Number of KRAS Tests Performed in France, 2007-2012
  • Table 12.55: Number of EGFR Tests Performed in France, 2008-2011
  • Table 12.56: Number of HER2, KRAS, EGFR and KIT Tests Performed in England, 2010 - 2011
  • Table 12.57: EU5 Marketed and Pipeline Companion Diagnostics, Number of Tests: Split by Type of Test, 2014 - 2024 (#: '000)
  • Table 12.58: EU5 Marketed and Pipeline Companion Diagnostics, Sales Forecast: Split by Type of Test, 2014 - 2024 (USD MM)
  • Table 12.59: EU5 KRAS Market, Number of Tests, 2014 - 2024 (# '000)
  • Table 12.60: EU5 KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.61: EU5 EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.62: EU5 EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.63: EU5 HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.64: EU5 HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Table 12.65: EU5 ALK Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Table 12.67: Other Companion Diagnostics in EU5, Number of Tests, 2014 - 2024 (# '000)
  • Table 12.68: Other Companion Diagnostics in EU5, Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.69: EU5 Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.70: EU5 Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.71: EU5 Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.72: EU5 Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.73: EU5 Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.74: EU5 Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.75: EU5 Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Table 12.76: EU5 Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Table 12.77: Abbott Laboratories Sales, 2013 - by Business Segments (USD million, %)
  • Table 12.78: Abbott Laboratories Sales, 2013 - Diagnostics Segments (USD million, %)
  • Table 12.79: Qiagen Sales, 2013 - by Business Segments (USD million, %)
  • Table 12.80: Qiagen Personalized Healthcare Sales, 2012 (USD million, %)
  • Table 12.81: Agilent Technologies Sales, 2013 - by Business Segments (USD million, %)
  • Table 12.82: Roche Group Sales, 2013 - by Business Segments (USD million, %)
  • Table 12.83: Roche Diagnostics Sales, 2013 - by Segments (USD million, %)
  • Table 12.84: Novartis Sales, 2013 - by Business Segments (USD million, %)
  • Table 12.85: bioMérieux Sales, 2013 - by Business Segments (USD million, %)
  • Table 12.86: Cost of Genome Sequencing (USD) - per Megabase, 2001-2012

List of Figures:

  • Figure 3.1: Segments of Personalized Medicine Diagnostics
  • Figure 3.2: Biomarker to Companion Diagnostics
  • Figure 4.1: NME Approved by the FDA, 2013 - With or Without Biomarker (%)
  • Figure 4.2: Companion Drugs Market, 2013 - By Leading Drugs (USD Million, %)
  • Figure 4.3: Companion Drugs Market, 2013 - By Leading Indication (USD Million, %)
  • Figure 4.4: Companion Drugs Market, 2013- by Leading Companies (USD million, %)
  • Figure 4.5: HER2 Expression in Breast Cancer Patients (%)
  • Figure 4.6: Herceptin Sales, 1998 - 2013 (USD Million)
  • Figure 4.7: EML4-ALK Expression in non-Small Cell Lung Cancer Patients (%)
  • Figure 4.8: Timeline for Development of Xalkori and Companion Diagnostic, 2005 - Current
  • Figure 4.9: Xalkori Sales, 2011- 2013 (USD Million)
  • Figure 4.10: BRAF V600E Expression in Metastatic Melanoma Patients (%)
  • Figure 4.11: Timeline for Development of Zelboraf and Companion Diagnostic, 2006 - Current
  • Figure 4.12: Zelboraf Sales, 2011- 2013 (USD Million)
  • Figure 4.13: Iressa Sales, 2005 - 2013 (USD Million)
  • Figure 4.14: G551D Mutation in Cystic Fibrosis Patients (%)
  • Figure 4.15 Kalydeco Sales, 2012 - 2013 (USD Million)
  • Figure 5.1: Global Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
  • Figure 5.2: Global Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
  • Figure 5.3: US Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
  • Figure 5.4: US Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
  • Figure 5.5: EU5 Companion Diagnostics Market, Number of Tests: Split by Category, 2014 - 2024 (# '000)
  • Figure 5.6: EU5 Companion Diagnostics Market, Sales Forecast: Split by Category, 2014 - 2024 (USD MM)
  • Figure 5.7: Global KRAS Market, Number of Tests, 2014 - 2024 (# '000)
  • Figure 5.8: Global KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 5.9: Global EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 5.10: Global EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 5.11: Global HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 5.12: Global HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 5.13: Global ALK Market, Number of Tests, 2014 - 2024 (# '000)
  • Figure 5.14: Global ALK Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 5.15 Other Companion Diagnostics, Global Number of Tests, 2014 - 2024 (# '000)
  • Figure 5.16: Other Companion Diagnostics, Global Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 5.17: Global Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 5.18: Global Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 5.19: Global Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 5.20: Global Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 5.21: Global Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 5.22: Global Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 5.23: Global Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 5.24: Global Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.1: US Marketed Companion Diagnostics, Number of Tests: Split by Type of Test, 2014 - 2024 (# '000)
  • Figure 6.2 US Marketed Companion Diagnostics, Sales Forecast: Split by Type of Test, 2014 - 2024 (USD MM)
  • Figure 6.3: US Pipeline Companion Diagnostics, Number of Tests, 2014 - 2024 (# '000)
  • Figure 6.4: US Pipeline Companion Diagnostics, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.5: US KRAS Market, Number of Tests, 2014 - 2024 (# '000)
  • Figure 6.6: US KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.7: US EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 6.8: US EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 6.9: US HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 6.10: US HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 6.11: US ALK Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 6.12: US ALK Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 6.13 Other Companion Diagnostics in the US, Number of Tests, 2014 - 2024 (# '000)
  • Figure 6.14: Other Companion Diagnostics in the US, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.15: US Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.16: US Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.17: US Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.18: US Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.19: US Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.20: US Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.21: US Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.22: US Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.23: Number of KRAS Tests Performed in France, 2007-2012
  • Figure 6.24: Number of EGFR Tests Performed in France, 2008-2012
  • Figure 6.25: Percentage of EGFR+ Patients in France
  • Figure 6.26: Number of HER2 Tests Performed in France, 2008-2011
  • Figure 6.27: Number of HER2, KRAS, EGFR and KIT Tests Performed in England, 2010 - 2011
  • Figure 6.28: Number of EGFR Tests Performed in the UK, August 2009 - July2010
  • Figure 6.29: EU5 Marketed Companion Diagnostics, Number of Tests: Split by Type of Test, 2014 - 2024 (# '000)
  • Figure 6.30: EU5 Marketed Companion Diagnostics, Sales Forecast: Split by Type of Test, 2014 - 2024 (USD MM)
  • Figure 6.31: EU5 Pipeline Companion Diagnostics, Number of Tests, 2014 - 2024 (# '000)
  • Figure 6.32: EU5 Pipeline Companion Diagnostics, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.33: EU5 KRAS Market, Number of Tests, 2014 - 2024 (# '000)
  • Figure 6.34: EU5 KRAS Market, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.35: EU5 EGFR Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 6.36: EU5 EGFR Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 6.37: EU5 HER2 Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 6.38: EU5 HER2 Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 6.39: EU5 ALK Market, Number of Tests: Split by Indication, 2014 - 2024 (# '000)
  • Figure 6.40: EU5 ALK Market, Sales Forecast: Split by Indication, 2014 - 2024 (USD MM)
  • Figure 6.41 Other Companion Diagnostics in EU5, Number of Tests, 2014 - 2024 (# '000)
  • Figure 6.42: Other Companion Diagnostics in EU5, Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.43: EU5 Metastatic NSCLC Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.44: EU5 Metastatic NSCLC Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.45: EU5 Metastatic Colorectal Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.46: EU5 Metastatic Colorectal Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.47: EU5 Breast Cancer Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.48: EU5 Breast Cancer Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 6.49: EU5 Melanoma Companion Diagnostic Tests, 2014 - 2024 (# '000)
  • Figure 6.50: EU5 Melanoma Companion Diagnostic Test Sales Forecast, 2014 - 2024 (USD MM)
  • Figure 7.1: Abbott Laboratories Sales, 2013 - by Business Segments (USD million, %)
  • Figure 7.2: Abbott Laboratories Sales, 2013-Diagnostics Segment (USD million, %)
  • Figure 7.3: Qiagen Sales, 2013 - Split by Business Segments (USD Million, %)
  • Figure 7.4: Qiagen Personalized Healthcare Sales, 2012 (USD million, %)
  • Figure 7.5: Agilent Technologies Sales, 2013 -Split by Business Segments (USD Million, %)
  • Figure 7.6: Roche: Phase 1 Pipeline Molecules (With and Without Companion Diagnostic Development)
  • Figure 7.7: Roche: Phase 2 Pipeline Molecules (With and Without Companion Diagnostic Development)
  • Figure 7.8: Roche: Phase 3 Pipeline Molecules (With and Without Companion Diagnostic Development)
  • Figure 7.9: Roche Group Sales, 2013-Split by Business Segments (USD Million, %)
  • Figure 7.10: Roche Diagnostics Sales, 2013-Split by Segments (USD Million, %)
  • Figure 7.11 Novartis Sales, 2013 -Split by Business Segments (USD Million, %)
  • Figure 7.12: bioMérieux Sales, 2013 -Split by Business Segments (USD Million, %)
  • Figure 8.1: Stakeholders in the Theranostics Market
  • Figure 8.2: Business Models for Companion Diagnostic Development
  • Figure 9.1: Efficacy Rate of Drugs (%)
  • Figure 9.2: Reasons for Drug Failure in Phase II of Clinical Trials, 2008-2010
  • Figure 9.3: Reasons for Drug Failure in Phase III of Clinical Trials, 2007-2010
  • Figure 9.4: Pipeline Drugs Attached with Biomarkers - by Phase of Development (%)
  • Figure 9.5: Cost of Genome Sequencing (USD) - per Mega base, 2001-2012

Listed Companies

The following companies have been mentioned in this report.

  • 1. 20/20 GeneSystems
  • 2. A&G Pharmaceutical
  • 3. AB Science
  • 4. Abbott Molecular
  • 5. Abkine Pharmaceutical
  • 6. AdeptBio
  • 7. Advanced Cell Diagnostics
  • 8. AES Laboratoire
  • 9. Aeterna Zentaris
  • 10. Affymetrix
  • 11. Agendia
  • 12. Agilent Technologies
  • 13. Agios Pharmaceuticals
  • 14. Almac
  • 15. AltheaDx
  • 16. Ameritox
  • 17. Amgen
  • 18. Amoy Diagnostics Co.
  • 19. Applied Biocode
  • 20. Argene
  • 21. Ariad Pharmaceuticals
  • 22. Arno Therapeutics
  • 23. AstraZeneca
  • 24. Asuragen
  • 25. AviaraDx
  • 26. Bayer
  • 27. Beckman Coulter
  • 28. Becton Dickinson
  • 29. Biocartis
  • 30. Biocrates Life sciences AG
  • 31. Biodesix
  • 32. BioFire Diagnostics
  • 33. Biogen Idec
  • 34. BioGenex Laboratories
  • 35. BioMarin Pharmaceutical
  • 36. BioMarker Strategies
  • 37. bioMérieux
  • 38. Biotage
  • 39. Boehringer Ingelheim
  • 40. Brain Resource Company
  • 41. Bristol Myers Squibb
  • 42. Bruker Daltonics
  • 43. CancerGuide Diagnostics
  • 44. Celgene
  • 45. Cell Signaling Technology (CST)
  • 46. Celldex Therapeutics
  • 47. Cellestis Limited
  • 48. Cenix BioScience
  • 49. Cephalon
  • 50. Cepheid
  • 51. ChemGenX Pharmaceuticals
  • 52. Claros Diagnostics
  • 53. Clovis Oncology
  • 54. CompanDx
  • 55. Corgenix
  • 56. Covance
  • 57. Crescendo Bioscience
  • 58. Curidium Medica
  • 59. Cyprotex
  • 60. Cytyc Corporation
  • 61. Daiichi Sankyo
  • 62. Dako
  • 63. Danaher
  • 64. Debiopharm Diagnostics
  • 65. Diagnocure
  • 66. DNA Vision
  • 67. Drug Response Dx
  • 68. Dx assays
  • 69. DxS
  • 70. Eisai
  • 71. Eli Lilly
  • 72. Empire genomics
  • 73. Endocyte
  • 74. Enzo Biochem
  • 75. Epic Sciences
  • 76. Epigenomics
  • 77. Epizyme
  • 78. ERYtech Pharma
  • 79. Evotec
  • 80. Exosome Diagnostics
  • 81. Flagship Biosciences
  • 82. Fougera pharmaceuticals
  • 83. Foundation Medicine
  • 84. Galena Biopharma
  • 85. Genentech
  • 86. GenMark Diagnostics
  • 87. Genomic Health
  • 88. Genoptix
  • 89. Gen-probe
  • 90. Genzyme Genetics
  • 91. GlaxoSmithKline
  • 92. Hatteras Venture Partners
  • 93. Horizon Discovery
  • 94. Ibis Biosciences
  • 95. ICON
  • 96. Ikonisys
  • 97. Illumina
  • 98. ImaginAb
  • 99. Imclone
  • 100. Immunex
  • 101. ImmusantT
  • 102. IncellDx
  • 103. Incyte
  • 104. InDex pharmaceuticals
  • 105. InsermTransfert
  • 106. Insight Genetics
  • 107. Intelligent Bio-Systems
  • 108. InterSouth partners
  • 109. Intezyne technology
  • 110. Inverness Medical Innovations
  • 111. Invitrogen
  • 112. Invivoscribe Technologies
  • 113. Ipsen
  • 114. Janssen Biotech
  • 115. Lab21
  • 116. LabCorp
  • 117. Leica Biosystems
  • 118. Life Technologies Corporation
  • 119. Luminex Corporation
  • 120. M2 gen
  • 121. MacroGenics
  • 122. MDx Health
  • 123. Merck
  • 124. Metabolon
  • 125. Millennium
  • 126. Molecular MD
  • 127. Monogram Biosciences
  • 128. Myriad Genetics
  • 129. Nanosphere
  • 130. Neovacs
  • 131. Nodality
  • 132. Novartis
  • 133. NuvOx
  • 134. OncoMed Pharmaceuticals
  • 135. On-Q-ity
  • 136. OPKO Health
  • 137. Optherion
  • 138. OriGene Technologies
  • 139. Orion Genomics
  • 140. Ortho-Clinical Diagnostics
  • 141. OSI Pharmaceuticals
  • 142. Oxford Biotherapeutics
  • 143. PamGene International B.V.
  • 144. Panacea Pharmaceuticals
  • 145. Personal Genome Diagnostics
  • 146. Pfizer
  • 147. Pharma Mar
  • 148. Pharmacyclics
  • 149. Plexxikon
  • 150. PrimeraDx
  • 151. Progenika Biopharma
  • 152. Psynova Neurotech
  • 153. Qiagen
  • 154. Quanterix Corporation
  • 155. Quest Diagnostics
  • 156. Quintiles Translational Corporation
  • 157. RAS Lifesciences
  • 158. Regulus Therapeutics
  • 159. ResearchDx
  • 160. Resonance Health
  • 161. Response Genetics
  • 162. RiboMed technologies
  • 163. Ridge Diagnostics
  • 164. Roche Laboratories
  • 165. Rules-Based Medicine
  • 166. Saladax Biomedical
  • 167. Sanofi
  • 168. Seattle Genetics
  • 169. Sequenom
  • 170. Shionogi
  • 171. Shire
  • 172. Siemens
  • 173. Signature Diagnostics
  • 174. Sirius Genomics
  • 175. Skuldtech
  • 176. Skyline Diagnostics
  • 177. STARLIMS technologies
  • 178. Sundance Diagnostics
  • 179. Syndax Pharmaceuticals
  • 180. Synthon Biopharmaceuticals
  • 181. Sysmex Inostics
  • 182. TcLand Expression
  • 183. Tesaro
  • 184. Thermo Fisher Scientific
  • 185. Third wave technologies
  • 186. TIB MolBiol
  • 187. Tocagen
  • 188. Tragara Pharmaceuticals
  • 189. Transgene
  • 190. Transgenomic
  • 191. Trimgen
  • 192. UCB Pharma
  • 193. Unidex
  • 194. Unilabs
  • 195. Validus
  • 196. Vatera Healthcare Partners
  • 197. Ventana Medical Systems
  • 198. Verastem
  • 199. Vertex Pharmaceuticals
  • 200. ViiV Healthcare
  • 201. Xdx
  • 202. Xenon Health
  • 203. Zinfandel

The following organizations have been mentioned in this report.

  • 1. AFSSAPS (Agence Française de Securité Sanitaire des Produits de Santé)
  • 2. American Society of Clinical Oncology (ASCO)
  • 3. BC Cancer Agency
  • 4. British In Vitro Diagnostics Association (BIVDA)
  • 5. Cancer Research, UK
  • 6. Center for Cooperative Research in Biosciences Biogene
  • 7. Centers for Medicare and Medicaid Services (CMS)
  • 8. Chinese Anti-Cancer Association (CACA)
  • 9. Committee for Medicinal Products for Human Use (CHMP)
  • 10. Cystic Fibrosis Foundation
  • 11. European Medicines Agency (EMA)
  • 12. European Personalized Medicine Organization (EPEMED)
  • 13. Food and Drug Administration (FDA)
  • 14. Haute Autorité de Santé (HAS)
  • 15. INCa
  • 16. Institut Mérieux
  • 17. Institute for Quality and Efficiency in Healthcare (IQWiG)
  • 18. Italian Medicines Agency (AIFA)
  • 19. Jichi Medical University
  • 20. Massachusetts General Hospital (MGH)
  • 21. Medical Devices Evaluation Committee (MDEC)
  • 22. Medical Research Council (MRC)
  • 23. Medical Services Advisory Committee (MSAC)
  • 24. Medicines and Healthcare products Regulatory Agency (MHRA)
  • 25. Ministry of Health, Labour and Welfare (MHLW)
  • 26. National Association of Testing Authorities (NATA)
  • 27. National Health Service (NHS)
  • 28. National Human Genome Research Institute (NHGRI)
  • 29. National Institute for Clinical Excellence (NICE)
  • 30. National Institutes of Health
  • 31. Novartis Institutes for Biomedical Research (NIBR)
  • 32. Pharmaceutical Benefits Advisory Committee (PBAC)
  • 33. Pharmaceutical Research and Manufacturers of America (PhRMA)
  • 34. Public Health England (PHE)
  • 35. Spanish Ministry of Health (MSC)
  • 36. Statutory Health Insurance (SHI)
  • 37. Technology Strategy Board (TSB)
  • 38. The Carlos III Health Institute
  • 39. The Federal Joint Committee (GBA)
  • 40. The Pharmaceuticals and Medical Devices Agency (PMDA)
  • 41. United Nations Population Division (UNPD)
  • 42. US Department of Energy
Back to Top